文献速递哮喘

哮喘急性发作的炎症与临床风险因素(ORACLE2):22项随机试验对照组的患者水平荟萃分析

Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.
PubMed 文献 · Lancet Respir Med · 2025-04-08

该研究系统检索1993至2021年随机对照试验,纳入22项试验对照组中6513例≥12岁哮喘患者,评估基线血嗜酸性粒细胞计数、FeNO等对重度哮喘急性发作的预测价值。结果显示血嗜酸性粒细胞计数或FeNO每增加10倍,发作风险分别增加48%和44%(高确定性证据),两者联合预测价值更高。

要点

  • 血嗜酸性粒细胞计数和FeNO每增加10倍,哮喘发作风险分别增加48%和44%。
  • 发作史、疾病严重度、低FEV1%和ACQ-5评分也是重要预测因素。
  • 支气管舒张剂可逆性增加与发作风险降低相关,主要在0%至25%区间。

核心结论

  • 血嗜酸性粒细胞计数、FeNO、哮喘发作史、疾病严重度、低FEV1%和症状评分是哮喘发作的关键预测因素。
  • 中度支气管舒张剂可逆性与重度哮喘发作风险降低相关。
  • 支持将血嗜酸性粒细胞和FeNO纳入临床风险分层以进行针对性风险降低。

研究设计与样本

  • 系统综述和荟萃分析,检索MEDLINE从1993年1月1日至2021年4月1日。
  • 纳入22项随机对照试验对照组中6513例≥12岁哮喘患者(4140例女性,2370例男性,3例缺失)。

主要发现

  • 血嗜酸性粒细胞计数和FeNO联合时风险高于任一单独因素。

关键数值与推荐

  • 重度哮喘发作定义为使用全身性糖皮质激素≥3天。

临床怎么用

  • 临床风险分层应纳入血嗜酸性粒细胞计数和FeNO以识别高风险患者。
  • 结合发作史、疾病严重度、FEV1%和ACQ-5评分综合评估哮喘发作风险。
  • 需探索更个体化的临床决策模型。

局限性

  • 潜在生态偏倚需量化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical risk factors for severe asthma attacks have been identified, but their incremental prognostic values are unclear. Additionally, the incremental contribution of type 2 inflammation, a common, treatable process, is undetermined. We aimed to quantify the prognostic value of baseline characteristics and type 2 inflammatory biomarkers, specifically blood eosinophil count and fractional exhaled nitric oxide (FeNO), to predict asthma attacks. METHODS: In this systematic review and meta-analysis of randomised controlled trials (RCTs), Oxford Asthma Attack Risk Scale 2 (ORACLE2), we searched MEDLINE from Jan 1, 1993, to April 1, 2021, for trials investigating fixed treatment regimen effects on asthma attack rates for at least 6 months with baseline blood eosinophil count and FeNO. Eligible participants were aged 12 years or older with asthma (any severity) who had been randomly assigned to the control group of an RCT. Relevant trials were manually retrieved and reviewed by two independent reviewers (SC and IDP). Disagreements were discussed with five reviewers. Individual patient data (IPD) for meta-analysis were requested from study authors. We investigated the rate of severe asthma attacks (≥3 days of systemic corticosteroids) for at least 6 months and prognostic effects of baseline blood eosinophil count and FeNO in control group participants. Rate ratios (RRs) with 95% CIs were derived for annualised asthma attack rates from negative binomial models adjusted for key variables, including blood eosinophil count and FeNO, and interactions between these type 2 inflammatory biomarkers were explored. Certainty of evidence was assessed using GRADE. The heterogeneity of the included studies and potential for ecological bias were quantified by the concordance statistic (C-statistic). This study was registered with PROSPERO, CRD42021245337. FINDINGS: We identified 976 potentially eligible studies. After automated screening, we manually reviewed 219 full-text articles. Of these, 19 publications comprising 23 RCTs were eligible. 6513 participants (4140 [64%] female; 2370 [36%] male; three missing) spanning 22 RCTs were included for data analysis. 5972 (92%) of 6513 patients had moderate-to-severe asthma. 4615 asthma attacks occurred during 5482 person-years of follow-up (annualised rate 0·84 per person-year). Higher blood eosinophil count or FeNO was linked to higher asthma attack risk (per 10-fold increase, RR 1·48 [95% CI 1·30-1·68] for blood eosinophil count and 1·44 [1·26-1·65] for FeNO; high-certainty evidence). Other prognostic factors were attack history (yes vs no, RR 1·94 [1·61-2·32]); disease severity (severe vs moderate, RR 1·57 [1·22-2·03]); FEV1 percentage predicted (FEV1%; per 10% decrease, RR 1·11 [1·08-1·15]); and 5-item Asthma Control Questionnaire score (ACQ-5; per 0·5 increase, RR 1·10 [1·07-1·13]). High blood eosinophil count and FeNO combined were associated with greater risk than either prognostic factor separately. Bronchodilator reversibility was associated with lower risk of severe asthma attacks (per 10% increase, RR 0·93 [0·90-0·96]), with the reduction observed primarily between 0% and 25%. Regarding heterogeneity of the included studies, the C-statistic ranged from 0·58 to 0·95, indicating major differences in patient and disease characteristics between studies. In the univariable meta-analysis per trial, we found substantial heterogeneity in associations between studies, with I2 statistics ranging from 0·56 to 0·97. INTERPRETATION: Blood eosinophil count, FeNO, asthma attack history, disease severity, low lung function (low FEV1%), and symptoms (ACQ-5 score) are key predictors of asthma attacks. Conversely, we found that moderate bronchodilator reversibility was associated with reduced risk. These findings from high-quality multinational RCTs support incorporation of blood eosinophils and FeNO into clinical risk stratification for targeted risk reduction. More individualised clinical decision-making models should be explored. FUNDING: National Institute of Health and Care Research Oxford Biomedical Research Centre; Association pulmonaire du Québec; Fonds de recherche du Québec-Santé; Québec Air-Intersectorialité-Respiratoire-Son network; Stichting Astma Bestrijding; Leiden University Fund; and Academy of Medical Sciences.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025. PMID: 40215991. doi:10.1016/S2213-2600(25)00037-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。